Publications by authors named "F Dalenc"

Claim this Profile
P
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort.
F Cherifi, L Cabel, C Bousrih, E Volant, F Dalenc

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Hope S Rugo, David W Cescon, Mark E Robson, Seock-Ah Im, Florence Dalenc

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of predicted sensitivity to endocrine therapy (SET2,3 index) and the recurrence score® in node-positive breast cancer: Independent validation in the PACS-01 trial.
Frédérique Penault-Llorca, Amelie Lusque, Thomas Filleron, Kevin Tran, Lili Du, Florence Dalenc

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.
Séverine Guiu, Judith Balmaña, Pablo Lemercier, Philippe Follana, Anthony Gonçalves, Florence Dalenc

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.
L Cabel, F Berger, T Bachelot, B Pistilli, F Dalenc

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis